Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both. METHODS: In a double-blind fashion, we randomly assigned 8561 patients to aliskiren (300 mg daily) or placebo as an adjunct to an angiotensin-converting-enzyme inhibitor or an angiotensin-receptor blocker. The primary end point was a composite of the time to cardiovascular death or a first occurrence of cardiac arrest with resuscitation; nonfatal myocardial infarction; nonfatal stroke; unplanned hospitalization for heart failure; end-stage renal disease, death attributable to kidney failure, or the need for renal-replacement therapy with no dialysis or transplantation available or initiated; or doubling of the baseline serum creatinine level. RESULTS: The trial was stopped prematurely after the second interim efficacy analysis. After a median follow-up of 32.9 months, the primary end point had occurred in 783 patients (18.3%) assigned to aliskiren as compared with 732 (17.1%) assigned to placebo (hazard ratio, 1.08; 95% confidence interval [CI], 0.98 to 1.20; P=0.12). Effects on secondary renal end points were similar. Systolic and diastolic blood pressures were lower with aliskiren (between-group differences, 1.3 and 0.6 mm Hg, respectively) and the mean reduction in the urinary albumin-to-creatinine ratio was greater (between-group difference, 14 percentage points; 95% CI, 11 to 17). The proportion of patients with hyperkalemia (serum potassium level, ≥6 mmol per liter) was significantly higher in the aliskiren group than in the placebo group (11.2% vs. 7.2%), as was the proportion with reported hypotension (12.1% vs. 8.3%) (P<0.001 for both comparisons). CONCLUSIONS: The addition of aliskiren to standard therapy with renin-angiotensin system blockade in patients with type 2 diabetes who are at high risk for cardiovascular and renal events is not supported by these data and may even be harmful. (Funded by Novartis; ALTITUDE ClinicalTrials.gov number, NCT00549757.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ACE inhibitors and ARBs should not be used together and should be used with caution with spironolactone to avoid hyperkalemia or AKI.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [259]
In the citing paper
“However, combination therapy was associated with a higher rate of hyperkalemia and AKI, 85,86”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [86]
In the citing paper
“Long-term outcome trials in patients with diabetes and CKD demonstrated no kidney or cardiovascular bene fi t of RAS blockade with combined therapy to block the RAS versus the single use of RAS inhibitors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [86]
In the citing paper
“Prior trials of dual renin–angiotensin system blockade have failed to show cardiovascular or kidney protection among patients with CKD and type 2 diabetes”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [25]
In the citing paper
“markedly lower than in trials of dual RAS blockade (4.8% with combination therapy with a direct renin inhibitor and an ACE inhibitor or ARB 20 and 9.2% with dual ACE inhibitor and ARB therapy 22 )”
From Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (2020) · cites this paper as [20]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationHaffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Self-citationTelmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
Self-citation
Research works printed but not linked: 1
- Pfeffer MA, 2010, Dial Cardiovasc Med, 15, 130
Cited by
Items 301–400 of 1,000
Watanabe, H., Martini, A. G., Brown, R. I., Liang, X., Medrano, S., Goto, S., Narita, I., Arend, L. J., Sequeira-Lόpez, M. L. S., & Gómez, R. A. (2021) · JCI Insight · doi:10.1172/jci.insight.154337 · Cited by 51
“On the other hand, dual blockade of the RAS with ARBs and ACEi may result in a reduction of proteinuria but worsen major renal outcomes (33), and a direct renin inhibitor in combination with an ACEi or ARB was reported to be harmful (34).”
RSSDI Guidelines for the management of hypertension in patients with diabetes mellitus
Kumar, V., Agarwal, S., Saboo, B., & Makkar, B. M. (2022) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-022-01143-7 · Cited by 58
“Two RAS blockers/ACE inhibitor 1 ARB or RAS blocker 1 renin inhibitor [131] High-risk diabetic patients More renal events”
BackgroundHeerspink, H. J. L., Jongs, N., Schloemer, P., Little, D. J., BRINKER, M. D., Tasto, C., Karpefors, M., Wheeler, D. C., Bakris, G. L., Perkovic, V., et al. (2023) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000000000243 · Cited by 48
Unmet need in diabetic nephropathy: failed drugs or trials?
de Zeeuw, D., & Heerspink, H. J. L. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(16)30045-6 · Cited by 46
Scheen, A. J., & Delanaye, P. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2016.12.010 · Cited by 47
“Attempts to better inhibit RAAS through dual blockade failed to show positive results with either a telmisartan–ramipril combination, as in ONTARGET [91], or the addition of the renin inhibitor aliskiren to either an ACEI or ARB in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) [92].”
BackgroundYamanouchi, M., SKUPIEN, J. K., Niewczas, M. A., Smiles, A. M., Doria, A., Stanton, R. C., Gałecki, A. T., Duffin, K. L., Pullen, N., Breyer, M. D., et al. (2017) · Kidney International · doi:10.1016/j.kint.2017.02.010 · Cited by 47
Hyperkalemia in patients with chronic renal failure
Seliger, S. L. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz231 · Cited by 46
Novel drugs and intervention strategies for the treatment of chronic kidney disease
Heerspink, H. J. L., & de Zeeuw, D. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12195 · Cited by 53
Brouwer, T. F., Vehmeijer, J. T., Kalkman, D. N., Berger, W. R., van den Born, B.-J. H., Peters, R. J., & Knops, R. E. (2018) · Diabetes Care · doi:10.2337/dc17-1722 · Cited by 44
Assessing the Validity of Surrogate Outcomes for ESRD: A Meta-Analysis
Jun, M., Turin, T. C., Woodward, M., Perkovic, V., Lambers Heerspink, H. J., Manns, B. J., Tonelli, M., & Hemmelgarn, B. R. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014040396 · Cited by 45
He, C. (2019) · Oxford University Press eBooks · doi:10.1093/med/9780190611620.003.0028 · Cited by 44
“ALTITUDE, 2012 (13) 8561, T2DM Terminated at 2.”
Luo, X., Xu, J., Zhou, S., Xue, C., Chen, Z., & Mao, Z. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000205 · Cited by 45
Whitlock, R. H., Leon, S. J., Manacsa, H., Askin, N., Rigatto, C., Fatoba, S., Farag, Y. M. K., & Tangri, N. (2023) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfad101 · Cited by 49
“Of 3482 unique records identified by the search strategy, 214 were selected for full text review, with 31 RCTs deemed eligible for inclusion [ 5 , 9 , 15 –43 ] (Fig.”
BackgroundResultSlowing the Progression of Diabetic Kidney Disease
Blazek, O., & Bakris, G. L. (2023) · Cells · doi:10.3390/cells12151975 · Cited by 47
Yao, L., Li, L., Li, X., Li, H., Zhang, Y., Zhang, R., Wang, J., & Xinmin, M. (2015) · BMC Complementary and Alternative Medicine · doi:10.1186/s12906-015-0826-x · Cited by 43
“controlling blood glucose levels in diabetes, it is still difficult to prevent kidney disease [12, 13].”
BackgroundParvanova, A. I., van der Meer, I. M., Iliev, I. P., Perna, A., Gaspari, F., Trevisan, R., Bossi, A. C., Remuzzi, G., Benigni, A., & Ruggenenti, P. L. (2013) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(13)70029-9 · Cited by 49
Protective effects of aliskiren and valsartan in mice with diabetic nephropathy
Wang, W., Qiu, L., Howard, A., Solis, N., Li, C., Wang, X., Kopp, J. B., & Levi, M. (2014) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320313507123 · Cited by 45
Global cardiovascular protection in chronic kidney disease
Ruiz‐Hurtado, G., Sarafidis, P. A., Fernández‐Alfonso, M. S., Waeber, B., & Ruilope, L. M. (2016) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2016.48 · Cited by 45
UK HARP-III Collaborative Group, Judge, P., Haynes, R., Herrington, W. G., Storey, B., Staplin, N., Bethel, A., Bowman, L., Brunskill, N., Cockwell, P., et al. (2016) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfw321 · Cited by 49
Self-citationFirst-line combination therapy versus first-line monotherapy for primary hypertension
Garjón, J., Saiz, L. C., Azparren, A., Elizondo, J. J., Gaminde, I., Ariz, M. J., & Erviti, J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010316.pub2 · Cited by 46
MicroRNAs and their delivery in diabetic fibrosis
Wonnacott, A., Denby, L., Coward, R. J., Fraser, D. J., & Bowen, T. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114045 · Cited by 45
Koh, E. S., Kim, G., & Chung, S. (2023) · Endocrinology and Metabolism · doi:10.3803/enm.2023.1764 · Cited by 46
“Several potential agents such as protein kinase C (PKC)-β inhibitor, endothelin type A receptor antagonist, pirfenidone, sulodexide, direct renin inhibitor, and nuclear 1 factor (erythroid-derived 2)-related factor 2 activator have all been suggested and introduced as new therapy of CKD but eventually most of them did…”
BackgroundGuidelines for the management of hypertension in CKD patients: where do we stand in 2024?
Theodorakopoulou, M. P., Ortíz, A., Fernández‐Fernández, B., Kanbay, M., Minutolo, R., & Sarafidis, P. A. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae278 · Cited by 56
Early Vascular Ageing – A Concept in Development
Nilsson, P. M. (2015) · touchREVIEWS in Endocrinology · doi:10.17925/ee.2015.11.01.26 · Cited by 49
Incidence, Severity, and Outcomes of AKI Associated with Dual Renin-Angiotensin System Blockade
Palevsky, P. M., Zhang, J. H., Seliger, S. L., Emanuele, N., Fried, L. F., & Study, F. T. V. N.-D. (2016) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.03470316 · Cited by 44
Sarafidis, P. A., Ortíz, A., Ferro, C. J., Halimi, J., Kreutz, R. H., Mallamaci, F., Mancia, G., & Wanner, C. (2021) · Journal of Hypertension · doi:10.1097/hjh.0000000000002776 · Cited by 45
“As a direct consequence of this, two previous trials on diabetic CKD evaluating the effects of double RAS blockade on the risk of ESKD and other hard renal outcomes were prematurely terminated because of increased risk of these side effects [17,18].”
ResultAlbuminuria is Not an Appropriate Therapeutic Target in Patients with CKD: The Con View
Fried, L. F., & Lewis, J. (2015) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10681014 · Cited by 42
Mechanisms of metabolic memory and renal hypoxia as a therapeutic target in diabetic kidney disease
Hirakawa, Y., Tanaka, T., & Nangaku, M. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12624 · Cited by 46
Ruilope, L. M., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., et al. (2014) · American Journal of Nephrology · doi:10.1159/000371497 · Cited by 41
Preventing and treating kidney disease in patients with type 2 diabetes
Delanaye, P., & Scheen, A. J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1551362 · Cited by 47
“Moreover, again safety was a concern, notably with a significantly higher risk of hyperkalemia [63].”
BackgroundResultHypertensive kidney disease: true epidemic or rare disease?
Stompór, T. P., & Perkowska‐Ptasińska, A. (2020) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.15150 · Cited by 50
“In several prospective randomized trials, subsequent to BP lowering albuminuria reduction was not followed by a decrease in the rate of GFR drop [57-60].”
BackgroundNovel Derivative of Bardoxolone Methyl Improves Safety for the Treatment of Diabetic Nephropathy
Huang, Z., Mou, Y., Xu, X., Zhao, D., Lai, Y., Xu, Y., Chen, C., Li, P., Peng, S., Tian, J., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00971 · Cited by 40
Present and Future in the Treatment of Diabetic Kidney Disease
Quiroga, B., Arroyo, D., & de Arriba, G. (2015) · Journal of Diabetes Research · doi:10.1155/2015/801348 · Cited by 40
“ALTITUDE [45] 8561 (ACE/ARB + aliskiren 300mg/day) Stopped due to adverse effects.”
BackgroundReview of Vasodilators in Acute Decompensated Heart Failure: The Old and the New
Carlson, M. D., & Eckman, P. (2013) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2013.05.007 · Cited by 41
Kidney Biomarkers and Decline in eGFR in Patients with Type 2 Diabetes
Garlo, K. G., White, W. B., Bakris, G. L., Zannad, F. M., Wilson, C., Kupfer, S., Vaduganathan, M., Morrow, D. A., Cannon, C. P., & Charytan, D. M. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.05280517 · Cited by 40
Schneider, M. P., Hilgers, K. F., Schmid, M. C., Hübner, S., Nadal, J., Seitz, D., Busch, M., Haller, H. G., Köttgen, A., Kronenberg, F., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0202604 · Cited by 45
Consenso latino-americano de hipertensão em pacientes com diabetes tipo 2 e síndrome metabólica
López-Jaramillo, P. A., Sanchez, R. A., Diaz, M., Cobos, L., Bryce, A., Parra-Carrillo, J. Z., Lizcano, F., Lanas, F. T., Sinay, I. R., Sierra, I. D., et al. (2014) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/0004-2730000003019 · Cited by 90
Saglimbene, V., Palmer, S. C., Ruospo, M., Natale, P., Maione, A., Nicolucci, A., Vecchio, M., Tognoni, G., Craig, J. C., Pellegrini, F., et al. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2018040443 · Cited by 39
Sarafidis, P., Papadopoulos, C. E., Kamperidis, V., Giannakoulas, G., & Doumas, M. (2021) · Hypertension · doi:10.1161/hypertensionaha.121.17005 · Cited by 39
Lerma, E., White, W. B., & Bakris, G. (2023) · Postgraduate Medicine · doi:10.1080/00325481.2022.2060598 · Cited by 39
“The hyperkalemia rates described above are lower than those reported in previous trials using dual RAS blockade in patients with T2D and CKD [69,70].”
BackgroundShin, J., Park, J. B., Kim, K., Kim, J. H., Yang, D. H., Pyun, W. B., Kim, Y. G., Kim, G., & Chae, S. C. (2015) · Clinical Hypertension · doi:10.1186/s40885-014-0013-2 · Cited by 42
“Combination therapy with angiotensin-receptor blockers and ACE inhibitors may be slightly more effective for reducing proteinuria but increases the risk for end-stage renal failure, stroke, and other CVD [81-83].”
BackgroundSternlicht, H., & Bakris, G. L. (2016) · Medical Clinics of North America · doi:10.1016/j.mcna.2016.08.001 · Cited by 46
Konvalinka, A., Zhou, J., Dimitromanolakis, A., Drabovich, A. P., Fang, F., Gurley, S. B., Coffman, T. M., John, R., Zhang, S., Diamandis, E. P., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.485326 · Cited by 42
“In clinical histopathology, tubular atrophy and interstitial fibrosis are the hallmarks of progression of all CKDs, implicating these cells in the pathophysiology leading to end stage renal disease.”
BackgroundInfluentialShlomai, G., Grassi, G. M., Grossman, E., & Mancia, G. (2013) · Journal of Clinical Hypertension · doi:10.1111/jch.12185 · Cited by 46
“terminated prematurely despite a decrease in UAE, because of increased CV events in the aliskiren arm.(28) These studies included high-risk patients, and in these”
BackgroundTocci, G., Barbato, E., Coluccia, R., Modestino, A., Pagliaro, B., Mastromarino, V., Giovannelli, F., Berni, A., & Volpe, M. (2015) · American Journal of Hypertension · doi:10.1093/ajh/hpv131 · Cited by 46
Ruiz‐Hurtado, G., Ruilope, L. M., de la Sierra, Á., Sarafidis, P. A., de la Cruz, J. J., Gorostidi, M., Segura, J., Vinyoles, E., & Banegas, J. R. (2016) · Diabetes Care · doi:10.2337/dc16-0748 · Cited by 43
“By contrast, despite its known predictive ability, recent data (38,39) have questioned the preventive capacity of drops in albuminuria.”
ResultFrom Cardiorenal Syndrome to Chronic Cardiovascular and Kidney Disorder: A Conceptual Transition
Zoccali, C., Mallamaci, F., Halimi, J., Rossignol, P., Sarafidis, P. A., Caterina, R. D., Giugliano, R. P., & Zannad, F. M. (2023) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.0000000000000361 · Cited by 48
Current perspectives on combination therapy in the management of hypertension
Mallat, S. G., Tanios, B. Y., & Itani, H. S. (2013) · Integrated Blood Pressure Control · doi:10.2147/ibpc.s33985 · Cited by 46
“In addition, in the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET), the combination of an ACEI and an ARB leads to increased incidence of adverse effects with no improvement in outcomes, and in the recently halted Aliskiren Trial In Type 2 Diabetes Using Cardio-Renal Diseas…”
ResultNew Management Strategies in Heart Failure
OWENS, A. T., Brozena, S. C., & Jessup, M. L. (2016) · Circulation Research · doi:10.1161/circresaha.115.306567 · Cited by 42
“A similar adverse event profile of aliskiren in diabetic patients was seen in another trial in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both.(29) These latter investigators concluded that there was no role for aliskiren in patients with type 2 diabetes mellitus; thi…”
ResultRenin Inhibition with Aliskiren: A Decade of Clinical Experience
Pantzaris, N., Karanikolas, E., Tsiotsios, K., & Velissaris, D. (2017) · Journal of Clinical Medicine · doi:10.3390/jcm6060061 · Cited by 43
Mitigating risk of aldosterone in diabetic kidney disease
Frimodt‐Møller, M., Persson, F., & Rossing, P. R. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000557 · Cited by 39
Self-citationWinkler, T. W., Rasheed, H., Teumer, A., Gorski, M., Rowan, B. X., Stanzick, K. J., Thomas, L. F., Tin, A., Hoppmann, A., Chu, A. Y., et al. (2022) · Communications Biology · doi:10.1038/s42003-022-03448-z · Cited by 39
“Details of the overall + difference test results are provided in Supplementary Note 1 and Supplementary Data 3, conditional difference analyses on known P Overall 5 × 10 − 8 variants in UMOD-PDILT in Supplementary Fig.”
BackgroundMethodInfluentialDiagnosis and Treatment of Diabetic Kidney Disease
Gosmanov, A. R., Wall, B. M., & Gosmanova, E. O. (2014) · The American Journal of the Medical Sciences · doi:10.1097/maj.0000000000000185 · Cited by 43
“and diuretics,(12,52) ACEi and calcium channel blockers,(53) dual RAS blockade with ACEi plus ARB(54) or ACEi or ARB and direct renin inhibitor.(55) The dual RAS blockade is not recommended due to absence of beneficial effects on CV disease and DKD progression and to increased adverse events.”
BackgroundMajor advancements in slowing diabetic kidney disease progression: focus on SGLT2 inhibitors
Bakris, G. L. (2019) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2019.05.009 · Cited by 37
SKOLNIK, N., & Style, A. J. (2021) · Diabetes Therapy · doi:10.1007/s13300-021-01050-w · Cited by 46
Therapies on the Horizon for Diabetic Kidney Disease
Khan, S. S., & Quaggin, S. E. (2015) · Current Diabetes Reports · doi:10.1007/s11892-015-0685-3 · Cited by 41
Challenges in the Management of Hypertension in Older Populations
Pont, L., & Alhawassi, T. M. (2016) · Advances in experimental medicine and biology · doi:10.1007/5584_2016_149 · Cited by 39
Rossing, P. R., Block, G. A., Chin, M. P., Goldsberry, A., Heerspink, H. J. L., McCullough, P. A., Meyer, C. J., Packham, D., Pérgola, P. E., Spinowitz, B., et al. (2019) · Kidney International · doi:10.1016/j.kint.2019.04.027 · Cited by 37
Microalbuminuria and cardiorenal risk: old and new evidence in different populations
Márquez, D. F., Ruiz‐Hurtado, G., Segura, J., & Ruilope, L. M. (2019) · F1000Research · doi:10.12688/f1000research.17212.1 · Cited by 41
Management of Hypertension in Diabetic Nephropathy: How Low Should We Go?
Sternlicht, H., & Bakris, G. L. (2016) · Blood Purification · doi:10.1159/000441264 · Cited by 45
Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression
Neuen, B. L., Tighiouart, H., Heerspink, H. J. L., Vonesh, E. F., Chaudhari, J., Miao, S., Chan, T. M., Fervenza, F. C., Floege, J., Goicoechea, M., et al. (2022) · Journal of the American Society of Nephrology · doi:10.1681/asn.2021070948 · Cited by 37
Yang, Q., Zheng, R., Wang, S., Zhu, J., Li, M., Wang, T., Zhao, Z., Xu, M., Lu, J., Chen, Y., et al. (2023) · Hypertension · doi:10.1161/hypertensionaha.123.20954 · Cited by 38
Tomey, M. I., & Winston, J. A. (2014) · Annals of Global Health · doi:10.1016/j.aogh.2013.12.007 · Cited by 45
Combined Angiotensin Receptor Modulation in the Management of Cardio-Metabolic Disorders
Paulis, L., Foulquier, S., Namsolleck, P., Recarti, C., Steckelings, U. M., & Unger, T. (2015) · Drugs · doi:10.1007/s40265-015-0509-4 · Cited by 39
“end-points: ONTARGET [44, 111] and ALTITUDE [112] advise against the use of dual RAS blockade.”
BackgroundInfluentialMesenchymal Stem Cells as Therapeutic Candidates for Halting the Progression of Diabetic Nephropathy
Paulini, J., Higuti, E., Bastos, R. M. C., Gomes, S. A., & Rangel, É. B. (2016) · Stem Cells International · doi:10.1155/2016/9521629 · Cited by 40
“The clinical trial involving aliskiren, a renin inhibitor, was stopped prematurely due to adverse events (hyperkalemia, hypotension, and cardiac arrest) and due to lack of benefit when compared to placebo [86].”
A Role for SGLT-2 Inhibitors in Treating Non-diabetic Chronic Kidney Disease
Vecchio, L. D., Beretta, A., Jovane, C., Peiti, S., & Genovesi, S. (2021) · Drugs · doi:10.1007/s40265-021-01573-3 · Cited by 41
Chu, L., Fuller, M. T., Jervis, K., Ciaccia, A., & Abitbol, A. (2021) · Clinical Therapeutics · doi:10.1016/j.clinthera.2021.07.015 · Cited by 43
Agarwal, R., Pitt, B., Rossing, P. R., Anker, S. D., Filippatos, G. S., Ruilope, L. M., Kovesdy, C. P., Tuttle, K. R., Vaduganathan, M., Wanner, C., et al. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.1505 · Cited by 36
Advances in treatment of hyperkalemia in chronic kidney disease
Sarafidis, P. A., Georgianos, P. I., & Bakris, G. L. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1083977 · Cited by 36
“Evidence derived from recent clinical trials clearly indicates that while dual RAAS blockade results in additive BP-lowering and antiproteinuric effects, it does not translate into cardiovascular or renal protection [37-39].”
BackgroundResultHypertension in Minority Populations: New Guidelines and Emerging Concepts
Rodríguez, F., & Ferdinand, K. C. (2015) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.08.004 · Cited by 39
Potassium Handling with Dual Renin-Angiotensin System Inhibition in Diabetic Nephropathy
Buren, P. N. V., ADAMS-HUET, B. A., Nguyen, M., Molina, C., & Toto, R. D. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07460713 · Cited by 38
Capítulo 3 - Avaliação Clínica e Complementar
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Figueiredo, C., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160153 · Cited by 51
State-of-the-art treatment of hypertension: established and new drugs
Burnier, M., Vuignier, Y., & Wuerzner, G. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht465 · Cited by 36
Proteomic Exploration of Common Pathophysiological Pathways in Diabetes and Cardiovascular Disease
Molvin, J., Jujić, A., Melander, O., Pareek, M., Råstam, L., Lindblad, U., Daka, B., Leósdóttir, M., Nilsson, P. M., Olsen, M. H., et al. (2020) · ESC Heart Failure · doi:10.1002/ehf2.13036 · Cited by 42
“The difference in heart failure (HF) burden is even more discouraging, with HF surpassing both myocardial infarction and stroke as the most common complication of type 2 diabetes.(4) Furthermore, the OR IG INAL RESEARCH ART ICLE”
BackgroundBovée, D. M., Ren, L., Uijl, E., Groningen, M. C. C., van Veghel, R., Garrelds, I. M., Domenig, O., Poglitsch, M., Zlatev, I., Kim, J. B., et al. (2021) · Hypertension · doi:10.1161/hypertensionaha.120.16876 · Cited by 39
Hypertension and the Role of Dietary Fiber
Nepali, P., Suresh, S., Pikale, G., Jhaveri, S., Avanthika, C., Bansal, M., Islam, R., & Chanpura, A. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101203 · Cited by 41
Viazzi, F. C., Bonino, B., Cappadona, F., & Pontremoli, R. (2016) · Internal and Emergency Medicine · doi:10.1007/s11739-016-1435-5 · Cited by 36
Sarafidis, P. A., Schmieder, R. E., Burnier, M., Persu, A., Januszewicz, A., Halimi, J., Arıcı, M., Ortíz, A., Wanner, C., Mancia, G., et al. (2024) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfae041 · Cited by 35
“Dual combination of an ACEi with an ARB or combination of aliskiren with any of the two is not recommended (CoR III; LoE A), because two relevant outcome trials were prematurely terminated as combination therapy was associated with increased risk of adverse events [45 , 46 ].”
ResultVitamin D and proteinuria: a critical review of molecular bases and clinical experience.
Pérez-Gómez, M. V., Ortíz, A., & Lorenzo-Sellares, V. (2013) · PubMed · doi:10.3265/nefrologia.pre2013.apr.12025 · Cited by 43
Huai, P., Han, H., Reilly, K. H., Guo, X., Zhang, J., & Xu, A. (2015) · Endocrine · doi:10.1007/s12020-015-0769-5 · Cited by 38
“subsequent severe illness and death [3].”
Future drug discovery in renin-angiotensin-aldosterone system intervention
Tamargo, M., & Tamargo, J. L. (2017) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2017.1335301 · Cited by 40
Xiang, L., Jiang, P., Zhou, L., Sun, X., Bi, J., Cui, L., Nie, X., Luo, R., Zhao, X., & Liu, Y. (2016) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2016/1064924 · Cited by 38
Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease
Benck, U., Krüger, B., & Schmitt, W. H. (2015) · New England Journal of Medicine · doi:10.1056/nejmc1500332 · Cited by 34
Chaudhry, K., & Karalliedde, J. J. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15765 · Cited by 42
“…two seminal trials, several studies interrogating alternative agents for prognostic benefits in CKD and a favourable safety profile did not bear fruit, 22,23 and for several years no other class of medications was shown to have a comparable profile in targeting the interrelation of DKD, CVD and HF.”
Sealey, J. E., Alderman, M. H., Furberg, C. D., & LARAGH, J. H. (2013) · American Journal of Hypertension · doi:10.1093/ajh/hpt034 · Cited by 34
Renin-Angiotensin-Aldosterone System Inhibition
Mercier, K., Smith, H. D., & Biederman, J. I. (2014) · Primary Care Clinics in Office Practice · doi:10.1016/j.pop.2014.08.002 · Cited by 37
Anderson, R. J., Bahn, G., Emanuele, N., Marks, J. B., Duckworth, W. C., & for the VADT Study Group (2014) · Diabetes Care · doi:10.2337/dc14-0284 · Cited by 33
Toto, R. D. (2018) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017121317 · Cited by 33
Challenges of Cardio-Kidney Composite Outcomes in Large-Scale Clinical Trials
Patel, R. B., ter Maaten, J. M., Ferreira, J. P., Causland, F. R. M., Shah, S. J., Rossignol, P., Solomon, S. D., Vaduganathan, M., Packer, M., Thompson, A., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.049514 · Cited by 37
Self-citationPharmacological interventions for heart failure in people with chronic kidney disease
Lunney, M., Ruospo, M., Natale, P., Quinn, R. R., Ronksley, P. E., Konstantinidis, I., Palmer, S. C., Tonelli, M. A., Strippoli, G. F., & Ravani, P. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012466.pub2 · Cited by 42
First-line combination therapy versus first-line monotherapy for primary hypertension
Garjón, J., Saiz, L. C., Azparren, A., Gaminde, I., Ariz, M. J., & Erviti, J. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd010316.pub3 · Cited by 35
The role of direct renin inhibitors in the treatment of the hypertensive diabetic patient
Riccioni, G. (2013) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018813490779 · Cited by 37
“Aliskiren in combination with ACEIs and ARBs Although in clinical studies aliskiren has been proved to reduce proteinuria, the early termination of the Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (ALTITUDE) confirms previous concerns about the full suppression of the RAAS, in th…”
ResultNassirpour, R., Raj, D., Townsend, R. R., & Argyropoulos, C. (2016) · Food and Chemical Toxicology · doi:10.1016/j.fct.2016.02.018 · Cited by 33
Drug discovery in renin–angiotensin system intervention: past and future
Williams, B. (2016) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944716642680 · Cited by 43
“The ALTITUDE study investigated the benefits of the DRI aliskiren as an add-on to an ACE-I or an ARB in patients with high cardiovascular or renal risk and type 2 diabetes [Parving et al. 2012].”
MethodOh, Y. J., Kim, S. M., Shin, B. C., Kim, H. L., Chung, J. H., Kim, A. J., Ro, H., Chang, J. H., Lee, H. H., Chung, W., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0170874 · Cited by 37
Reduction of cardiovascular risk in chronic kidney disease by mineralocorticoid receptor antagonism
Epstein, M. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00289-2 · Cited by 36
Jhund, P. S., McMurray, J. J. V., Chaturvedi, N., Brunel, P., Desai, A. S., Finn, P. V., Haffner, S. M., Solomon, S. D., Weinrauch, L. A., Claggett, B. L., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv295 · Cited by 32
“enrolled in the Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints (ALTITUDE).(14) The primary results of ALTITUDE did not show any benefit of adding aliskiren to a standard therapy of an angiotensin-converting enzyme inhibitor (ACEI) or an angiotensin receptor blocker (ARB) in type 2 diabetic patients wit…”
BackgroundMethodInfluentialSelf-citationPredictors of Congestive Heart Failure after Treatment with an Endothelin Receptor Antagonist
Hoekman, J., Heerspink, H. J. L., Viberti, G. C., Green, D., Mann, J. F. E., & de Zeeuw, D. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07040713 · Cited by 33
Kommentar zur 2013-ESH/ESC-Leitlinie zum Management der arteriellen Hypertonie
Kintscher, U., Böhm, M., Goss, F., Kolloch, R. E., Kreutz, R. H., Schmieder, R. E., & Schunkert, H. (2014) · Der Kardiologe · doi:10.1007/s12181-014-0575-y · Cited by 38
Koid, S. S., Ziogas, J., & Campbell, D. J. (2014) · Hypertension · doi:10.1161/hypertensionaha.113.02902 · Cited by 35
Metadata
- Authors
- Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., Richard, A., Xiang, Z., Brunel, P., & Pfeffer, M. A.
- Affiliations
- University of Copenhagen (DK)
- Brigham and Women's Hospital (US)
- The University of Texas at San Antonio Health Science Center (US)
- Imperial College London (GB)
- Steno Diabetes Centers (DK)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-12-06
- Volume
- 367
- Issue
- 23
- Pages
- 2204-2213
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138862624
- Cited by
- 1,319
- References
- 40
- Citations by year
- 2026: 30 · 2025: 41 · 2024: 52 · 2023: 68 · 2022: 61 · 2021: 75 · 2020: 73 · 2019: 96 · 2018: 93 · 2017: 124 · 2016: 117 · 2015: 151 · 2014: 166 · 2013: 159 · 2012: 11
- FWCI
- 100.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- IRIS (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Open Access CRIS of the University of Bern
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- aliskiren, type 2 diabetes, chronic kidney disease, renin-angiotensin system blockade, ACE inhibitors, angiotensin receptor blockers, cardiovascular events, end-stage renal disease, hyperkalemia, hypotension, albumin-creatinine ratio, blood pressure reduction, cardiorenal outcomes
- MeSH terms
- Renin Inhibitors, Aged, Amides, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Fumarates, Humans, Hyperkalemia, Hypokalemia, Kidney Diseases, Male, Middle Aged, Patient Dropouts, Treatment Failure, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.